Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are seeking the best dose of revumenib (SNDX-5613) to give with chemotherapy in people with acute myeloid leukemia (AML). The people in this study have AML that has not yet been treated. In addition, their cancers have a mutation (change) in the KMT2Ar, NPM1c, or NUP98r gene.
Chordoma is a type of bone cancer that develops in the spine or the base of the skull. Researchers are doing this study to learn if ERAS-601 is safe and works well in people with chordoma. The people in this study have chordoma that is inoperable (cannot be taken out with surgery) or has spread.
Women with a mutation in the BRCA1 or BRCA2 genes are at increased risk for hereditary breast and ovarian cancer. However, the cancer risk estimates for these gene mutations are currently wide-ranging and non-specific. A new form of genetic testing, called "genetic risk modifier testing," may give women with BRCA1/2 gene mutations more specific estimates of their risk of developing breast cancer.
Rhabdomyosarcoma (RMS) is a type of cancer that occurs in the soft tissues in the body. Researchers in this study are comparing different chemotherapy-based treatments for children and young adults with very low-risk RMS, low-risk RMS, and RMS with DNA mutations, with treatment tailored to the predicted aggressiveness of each patient's cancer. The standard chemotherapy drugs participants will receive include vincristine, dactinomycin, and cyclophosphamide.
The purpose of this study is to find the highest dose of vorasidenib that can be given safely in combination with pembrolizumab immunotherapy in people with astrocytoma that came back or continued to grow despite treatment and contains a mutation in the IDH-1 protein.
The purpose of this study is to assess the safety and effectiveness of different combinations of drugs to treat advanced clear cell renal cell carcinoma, a type of kidney cancer, in patients who have not received any prior treatment or who have recently developed worsening disease while receiving immunotherapy that targets the PD-1/PD-L1 proteins.
Researchers are assessing nivolumab and ipilimumab immunotherapy with or without cabozantinib to treat advanced nasopharyngeal cancer. The people in this study have nasopharyngeal cancer that recurred (came back) or metastasized (spread). In addition, the cancer cannot be cured with other therapies.
Researchers want to see if bemdaneprocel improves symptoms in people with Parkinson's disease (PD). PD symptoms are due to a loss of cells that make a chemical in your brain called dopamine.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are assessing several drugs given together to treat monoclonal gammopathy of renal significance (MGRS). MGRS happens when you have an abnormal protein (called M-protein) in your blood and it damages your kidneys.
